Compartir
Biolust, Brain Death, and the Battle Over Organ Transplants: America's Biotech Juggernaut and Its Japanese Critics (en Inglés)
William R. LaFleur
(Autor)
·
Edward R. Drott
(Ilustrado por)
·
Bloomsbury Academic
· Tapa Blanda
Biolust, Brain Death, and the Battle Over Organ Transplants: America's Biotech Juggernaut and Its Japanese Critics (en Inglés) - LaFleur, William R. ; Drott, Edward R.
$ 69.102
$ 115.170
Ahorras: $ 46.068
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Estados Unidos
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Jueves 15 de Agosto y el
Lunes 26 de Agosto.
Lo recibirás en cualquier lugar de Argentina entre 1 y 3 días hábiles luego del envío.
Reseña del libro "Biolust, Brain Death, and the Battle Over Organ Transplants: America's Biotech Juggernaut and Its Japanese Critics (en Inglés)"
William LaFleur (1936-2010), an eminent scholar of Japanese studies, left behind a substantial number of influential publications, as well as several unpublished works. The most significant of these examines debates concerning the practice of organ transplantation in Japan and the United States, and is published here for the first time.This provocative book challenges the North American medical and bioethical consensus that considers the transplantation of organs from brain dead donors as an unalloyed good. It joins a growing chorus of voices that question the assumption that brain death can be equated facilely with death. It provides a deep investigation of debates in Japan, introducing numerous Japanese bioethicists whose work has never been treated in English. It also provides a history of similar debates in the United States, problematizing the commonly held view that the American public was quick and eager to accept the redefinition of death.A work of intellectual and social history, this book also directly engages with questions that grow ever more relevant as the technologies we develop to extend life continue to advance. While the benefits of these technologies are obvious, their costs are often more difficult to articulate. Calling attention to the risks associated with our current biotech trajectory, LaFleur stakes out a highly original position that does not fall neatly onto either side of contemporary US ideological divides.
